Evidence map›Paper›PMID 36505874›Full record

ReviewFrontiers in oncology2022

Circ_0007534 as new emerging target in cancer: Biological functions and molecular interactions.

Bowen Liu, Chengbin Dong, Quan Chen, Zhenhua Fan, Yu Zhang, Yifan Wu, Ting Cui, Fuquan Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bowen LiuDepartment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Chengbin DongDepartment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Quan ChenDepartment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Zhenhua FanDepartment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yu ZhangDepartment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yifan WuDepartment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Ting CuiDepartment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Fuquan LiuDepartment of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNA (circRNAs), an important member of the non-coding RNA (ncRNA) family, are widely expressed in a variety of biological cells. Owing to their stable structures, sequence conservations, and cell- or tissue-specific expressions, these RNA have become a popular subject of scientific research. With the development of sequencing methods, it has been revealed that circRNAs exert their biological function by sponging microRNAs (miRNAs), regulating transcription, or binding to proteins. Humans have historically been significantly impacted by various types of cancer. Studies have shown that circRNAs are abnormally expressed in various cancers and are involved in the occurrence and development of malignant tumors, such as tumor cell proliferation, migration, and invasion. As one of its star molecules, circ_0007534 is upregulated in colorectal, cervical, and pancreatic cancers; is closely related to the occurrence, development, and prognosis of tumors; and is expected to become a novel tumor marker and therapeutic target. This article briefly reviews the expression and mechanism of circ_0007534 in malignant tumors based on the domestic and foreign literature.

Indexed as

circ_0007534circRNAexpressionmigrationproliferationtumor

Identifiers

PMID36505874
PMCPMC9730518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.